Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs Medtronic PLC — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $32.55, while Medtronic PLC trades at $90.5 (market cap $116.07B). The key difference: Medtronic PLC pays a 3.18% dividend while MicroSectors FANG and Innovation 3X Leveraged ETN pays none, and MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, Medtronic PLC nearer its low. Which is the better fit depends on your goals.
| FNGU | MDT | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $36.15 | $105.35 |
52-Week Low | $13.73 | $73.75 |
Market Cap | — | $116.07B |
Enterprise Value | — | $134.82B |
Dividend Yield | — | 3.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3X leveraged ETN tracking the FANG+ Index, trades at $32.53, down 3.47% on the day. Technical indicators show a bullish trend with moving averages supporting upside, though RSI levels suggest overbought conditions. Recent news highlights extreme volatility, with a 16% single-session loss reported on June 5, 2026, underscoring the product's leveraged risk.
The outlook for FNGU hinges on continued strength in mega-cap tech stocks, but risks are elevated due to leverage decay and market volatility. Investors face potential for amplified gains or losses, with sentiment cautious amid recent sharp declines. Careful risk management is essential given the ETN's structure.
Medtronic (MDT) trades at $89.99, up 0.65% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, 13.2% net income margin, and positive cash flow trends. Recent product innovations including the Hugo robotic surgery platform and AI surgical tools position MDT for growth. Analyst consensus remains strongly positive with 60% buy ratings and $98.75 price target.
MDT presents a compelling investment case with steady revenue growth, dividend aristocrat status, and technological leadership in medical devices. Key risks include increasing debt levels and competitive pressures from Intuitive Surgical. The stock's current valuation at 24.31 P/E appears reasonable given growth prospects, with upside potential to consensus targets if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
